Glaukos signs exclusive license deal with RevOpsis for retinal biologic RO-104
Bitget2026/10/08 11:00Glaukos entered an exclusive license deal with RevOpsis Therapeutics for RO-104, a tri-specific biologic for retinal vascular diseases. Agreement covers development and commercialization in neovascular age-related macular degeneration, diabetic eye disease, retinal vein occlusion. Deal grants exclusive access to RevOpsis’ RevMod platform to generate up to four additional next-generation retinal biologic candidates. RO-104 is designed to block VEGF-A, VEGF-C, Ang-2, three angiogenic pathways implicated in retinal vascular disease progression. Financial terms were not disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Glaukos Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261008992641) on October 08, 2026, and is solely responsible for the information contained therein.
- Glaukos entered an exclusive license deal with RevOpsis Therapeutics for RO-104, a tri-specific biologic for retinal vascular diseases.
- Agreement covers development and commercialization in neovascular age-related macular degeneration, diabetic eye disease, retinal vein occlusion.
- Deal grants exclusive access to RevOpsis’ RevMod platform to generate up to four additional next-generation retinal biologic candidates.
- RO-104 is designed to block VEGF-A, VEGF-C, Ang-2, three angiogenic pathways implicated in retinal vascular disease progression.
- Financial terms were not disclosed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
